Pretransplant inflammation: A risk factor for delayed graft function?

Journal of Nephrology

Volumn 21, Issue 2, 2008, Pages 221-228

  Lauzurica, Ricardo ^a   Pastor, Mari Cruz ^a   Bayés, Beatriz ^a   Hernández, Jose María ^a   Bonet, Josep ^a   Doladé, María ^a   Navarro, Maru ^a   Romero, Ramón ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

CRP; Delayed graft function; IL 6; PAPP A; Pre TR inflammation; TIVF alpha

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CALCINEURIN INHIBITOR; CD45 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN A; INTERLEUKIN 6; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PREGNANCY ASSOCIATED PLASMA PROTEIN A; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; AUTACOID;

ADULT; AGE; ARTICLE; CADAVER DONOR; COLD ISCHEMIA; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DIALYSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT RECIPIENT; HISTOCOMPATIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; RETREATMENT; RISK FACTOR; BLOOD; CADAVER; KIDNEY; MIDDLE AGED; PATHOLOGY; REPERFUSION INJURY;

ADULT; C-REACTIVE PROTEIN; CADAVER; DELAYED GRAFT FUNCTION; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; REPERFUSION INJURY; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 50049089889     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol. 2003;14:2199-2210.
2. Bonventre JV. Pathophysiology of ischemic acute renal failure: inflammation, lung-kidney cross-talk, and biomarkers. Contrib Nephrol. 2004;144:19-30.
3. Rosen S, Heyman SN. Difficulties in understanding human "acute tubular necrosis": limited data and flawed animal models. Kidney Int. 2001;60:1220-1224.
4. Bonventre JV, Zuk A. Ischemic acute renal failure: an inflammatory disease? Kidney Int. 2004;66:480-485
5. Solez K, Racusen LC, Marcussen N, et al. Morphology of ischemic acute renal failure, normal function, and cyclosporine toxicity in cyclosporine-treated renal allograft recipients. Kidney Int. 1993;43:1058-1067.
6. Marcén R, Orofino L, Pascual J, et al. Delayed graft function does not reduce the survival of renal transplant allografts. Transplantation. 1998;66:461-466.
7. Lechevallier E, Dussol B, Luccioni A, et al. Posttransplantation acute tubular necrosis: risk factors and implications for graft survival. Am J Kidney Dis. 1998;32:984-991.
8. Lebranchu Y, Halimi JM, Bock A, et al; the MOST International Study Group. Delayed graft function: risk factors, consequences and parameters affecting outcome-results from MOST, a multinational observational study. Transplant Proc. 2005;37:345-347.
9. Loverre A, Ditonno P, Crovace A, et al. Ischemia-reperfusion induces glomerular and tubular activation of proinflammatory and antiapoptotic pathways: differential modulation by rapamycin. J Am Soc Nephrol. 2004;15:2675-2686.
10. Thiagarajan RR, Winn RK, Harlan JM. The role of leukocyte and endothelial adhesion molecules in ischemia-reperfusion injury. Thromb Haemost. 1997;78:310-314.
11. Pereira JG, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1β, TNFα and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int. 1994;45:890-896.
12. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899-1911.
13. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648-658.
14. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000;35:469-476.
15. Wald NJ, Watt HC, Hackshaw A. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. N Engl J Med. 1999;341:461-467.
16. Bayes-Genis A, Conover CHA, Overgaard M, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med. 2001;345:1022-1029.
17. Kalousova M, Sulkova S, Fialova L, et al. Glycoxidation and inflammation in chronic haemodyalisis patients. Nephrol Dial Transplant. 2003;18:2577-2581.
18. Lauzurica R, Pastor C, Bayes B, Hernandez JM, Romero R. Pretransplant pregnancy-associated plasma protein-A as a predictor of chronic allograft nephropathy and posttransplant cardiovascular events. Transplantation. 2005;80:1441-1446.
19. Lauzurica R, Teixido J, Serra A, et al. Hydration and mannitol reduce the need for dialysis in cadaveric kidney transplant recipients treated with CyA. Transplant Proc. 1992;24:46-47.
20. Shoskes D, Lapierre Ch, Cruz-Corerra M, et al. Beneficial effects of the bioflavonoids curcumin and quercetin on early function in cadaveric renal transplantation: a randomized placebo controlled trial. Transplantation. 2005;80:1556-1559.
21. Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. Lancet. 2004;364:1814-1827.
22. Araki M, Schenk AD, Fairchild RL. Cytokines and chemokines: roles in the pathophysiology and therapy of ischemia and reperfusion injury. Curr Opin Organ Transplant. 2004;9:139-144.
23. Donckier V, Loi P, Closset J, et al. Preconditioning of donors with interleukin 10 reduces hepatic ischemia-reperfusion injury after liver transplantation in pigs. Transplantation. 2003;75:902-904.
24. Teoh N, Leclercq I, De la Pena A, Farrell G. Low-dose TNF-α protects against hepatic ischemia-reperfusion injury in mice: implications for preconditioning. Hepatology. 2003;37:118-128.
25. Donnahoo KK, Shames BD, Harken AH, Meldrum DR. Review article: the role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol. 1999;162:196-203.
26. Azuma H, Nadean K, Takada M, Mackenzie HS, Tilney NL. Cellular and molecular predictors of chronic renal dysfunction after initial ischemia/ reperfusion injury of a single kidney. Transplantation. 1997;64:190-197.
27. Donnahoo KK, Meldrum DR, Shenkar R, Chung Ch, Abraham E, Harken AH. Early renal ischemia, with or without reperfusion, activates NFκB and increases TNF-α bioactivity in the kidney. J Urol. 2000; 163:1328-1332.
28. Cugini D, Azzollini N, Gagliardini E, et al. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia-reperfusion. Kidney Int. 2005;67:1753-1761.
29. Sekido N, Mukaida N, Harada A, Nakanishi I, Watanabe Y, Matsushima K. Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature. 1993;365:654-657.
30. Araki M, Fahmy N, Zhou L, et al. Expression of IL-8 during reperfusion of renal allografts is dependent on ischemic time. Transplantation. 2006;81:783-788.
31. Sadeghi M, Daniel V, Naujokat C, Mehrabi A, Opelz G. Association of high pretransplant sIL-6R plasma levels with acute tubular necrosis in kidney graft recipients. Transplantation. 2006;81:1716-1724.
32. Lauzurica R, Pastor MC, Bayes B, et al. Pretransplant inflammation: a risk factor for post-renal transplant acute tubular necrosis? Am J Transplant. 2005;5(Suppl 11):A678:329.
33. Lawrence JB, Oxvig C, Overgaard MT, et al. The insulin-like growth factor (IGF) dependent IGF binding protein-4 is pregnancy-associated plasma protein-A. Proc Natl Acad Sci U S A. 1999;96:3149-3153.
34. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol. 2005;16:3015-3026.
35. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation. 2006;81:643-654.
36. Fernandez M, Medina A, Santos F, et al. Exacerbated inflammatory response induced by insulin-like growth factor I treatment in rats with ischemic acute renal failure. J Am Soc Nephrol. 2001;12:1900-1907.
37. McGeeham GM, Becherer JD, Bast RC, et al. Regulation of tumour necrosis factor-a processing by a metalloproteinase inhibitor. Nature. 1994;370:558-561.
38. Gearing AJ, Beckett P, Christodoulou M, et al. Processing of tumour necrosis factor-a precursor by metalloproteinases. Nature. 1994;370:555-557.
39. Mohler KM, Sleath PR, Fitzner JN, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature. 1994;370:218-220.
40. Basile DP, Fredrich K, Weihrauch D, Hattan N, Chilian WM. Angiostatin and matrix metalloproteinase expression following ischemic renal failure. Am J Physiol Renal Physiol. 2004;286:F893-F902.
41. Kuyvenhoven JP, Molenaar Q, Verspaget HW, et al. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation: the effect of aprotinin and the relation to ischemia/ reperfusion injury. Thromb Haemost. 2004;91:506-513.
42. Lalu MM, Csonka C, Giricz Z, Csont T, Schulz R, Ferdinandy P. Preconditioning decreases ischemia/reperfusion-induced release and activation of metalloproteinase-2. Biochem Biophys Res Commun. 2002;296:937-941.
43. Soccal PM, Gasche Y, Miniati DN, et al. Matrix metalloproteinase inhibition decreases ischemia-reperfusion injury after lung transplantation. Am J Transplant. 2004;1:41-50.